MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo
Lorna R. Fiedler, Kathryn Chapman, Min Xie, Evie Maifoshie, Micaela Jenkins, Pelin Golforoush, Mohamed Bellahcene, Michela Noseda, Dörte Faust, Ashley Jarvis, Gary Newton, Marta Paiva, Mutsuo Harada, Daniel J. Stuckey, Weihua Song, Josef Habib, Priyanka Narasimhan, Rehan Aqil, Devika Sanmugalingam, Robert Yan, Lorenzo Pavanello, Motoaki Sano, Sam C. Wang, Robert D. Sampson, Sunthar Kanayaganam, George E. Taffet, Lloyd H. Michael, Mark L. Entman, Tse‐Hua Tan, Siân E. Harding, Caroline M. R. Low, Catherine Tralau-Stewart, Trevor R. Perrior, Michael Schneider
Abstract
(Cell Stem Cell 24, 579–591.e1–e12; April 4, 2019) In the originally published version of our manuscript, one of the authors was incorrectly listed as “Narasimham, P.” To address this, we have now corrected the spelling of the name both here and in our original article online to “Narasimhan, P.” We apologize for the oversight and for any resulting confusion. MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In VivoFiedler et al.Cell Stem CellMarch 7, 2019In BriefUsing human iPSC-derived cardiomyocytes to enhance cardiac drug discovery, Fiedler et al. performed MAP4K4 target validation by gene silencing in this human model. MAP4K4 inhibitors augment human cardiomyocyte viability and function in 2D culture and 3D engineered heart tissue. An exemplar successfully reduces infarct size in proof-of-principle studies in mice. Full-Text PDF Open Access